Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Assets (2021 - 2025)

Historic Return on Assets for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to 0.47%.

  • 4D Molecular Therapeutics' Return on Assets fell 2300.0% to 0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.47%, marking a year-over-year decrease of 2300.0%. This contributed to the annual value of 0.36% for FY2024, which is 200.0% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Return on Assets stood at 0.47% for Q3 2025, which was down 2300.0% from 0.4% recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Return on Assets high stood at 0.18% for Q2 2024, and its period low was 0.47% during Q3 2025.
  • Its 5-year average for Return on Assets is 0.3%, with a median of 0.28% in 2024.
  • Its Return on Assets has fluctuated over the past 5 years, first soared by 2200bps in 2024, then tumbled by -2300bps in 2025.
  • 4D Molecular Therapeutics' Return on Assets (Quarter) stood at 0.24% in 2021, then crashed by -65bps to 0.4% in 2022, then rose by 28bps to 0.29% in 2023, then increased by 4bps to 0.28% in 2024, then plummeted by -69bps to 0.47% in 2025.
  • Its last three reported values are 0.47% in Q3 2025, 0.4% for Q2 2025, and 0.33% during Q1 2025.